Exelixis Inc. Common Stock vs Solaris Energy Infrastructure Inc. Class A Common Stock — how do they compare? Exelixis Inc. Common Stock trades at $61.28 (market cap $14.75B), while Solaris Energy Infrastructure Inc. Class A Common Stock trades at $67.48 (market cap $5.12B). The key difference: Exelixis Inc. Common Stock is far larger — about 2.9× Solaris Energy Infrastructure Inc. Class A Common Stock's market cap, and Solaris Energy Infrastructure Inc. Class A Common Stock pays a 0.62% dividend while Exelixis Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Exelixis Inc. Common Stock for 3 Days and Solaris Energy Infrastructure Inc. Class A Common Stock for 0 Days on average.
| EXEL | SEI | |
|---|---|---|
Market Cap | $14.75B | $5.12B |
Volume | 2,624,658 | 2,532,496 |
Sector | Health | Energy |
52-Week High | $60.99 | $82.88 |
52-Week Low | $34.54 | $40.64 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $14.07B | $6.81B |
Dividend Yield | — | 0.62% |
Signals from Pluang's Aura AI — not financial advice
EXEL trades at $59.51, down 0.52% on the day but near its 52-week high of $61.66 reached on October 12, 2026. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Recent news highlights include a three-month FDA review delay for zanzalintinib but continued growth in CABOMETYX revenue, which surpassed $3 billion annually.
The outlook remains positive with strong profitability metrics (35.33% net margin, 44.39% ROE) and projected revenue growth to $2.4 billion in 2026. Key risks include regulatory delays for new drug approvals and competitive pressures in oncology. Analyst consensus is mixed with 48% buy ratings but a price target of $52.33 suggesting potential downside from current levels.
SEI (Solaris Energy Infrastructure) trades at $77.83, down 1.83% today, but maintains strong analyst support with 9 unanimous buy ratings and a $100.56 consensus price target. The stock shows positive momentum with three consecutive quarterly earnings beats and projected revenue growth from $622M in 2025 to $762M in 2026. Recent technical analysis indicates neutral signals with support at $76 and resistance at $79.
The outlook remains positive given strong earnings performance and expansion initiatives, though elevated valuation ratios (P/E of 98.52) and significant debt issuance ($1.25B notes) present risks. The upcoming Q3 2026 earnings report on October 21 will be crucial for validating growth trajectory amid energy sector volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →Solaris Energy Infrastructure, Inc. provides mobile power generation, control, and distribution equipment and logistics equipment for managing raw materials at well sites, operating through its Solaris Power Solutions and Solaris Logistics Solutions segments for data center, energy, commercial, and industrial customers.
Read more on SEI →